Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering
Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering
Details : This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for gener...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 26, 2020
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : National Anti-Doping Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sotalol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2019
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : National Anti-Doping Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia
Details : Sotalol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tachycardia, Ventricular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2013
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
